STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact
Expert Review of Clinical Pharmacology · 02.12.2023 · 16 (12) · 1175-1185
DOI: 10.1080/17512433.2023.2280219 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 10.11.2023. Verfasst von Siobhán McGettigan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University College Cork, Cork, Ireland. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Potentially Inappropriate Medication List. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
INTRODUCTION: STOPP/START criteria for potentially inappropriate medications (PIMs, STOPP) and potential prescribing omissions (PPOs, START) have gained considerable interest and traction since they were first published in 2008. This review focuses on their uptake and impact in various clinical settings. AREAS COVERED: STOPP/START criteria, now in their third iteration, are explicit criteria designed to facilitate detection of common and clinically important PIMs and PPOs during routine medication review in any clinical setting. We examine the influence of the criteria, particularly in clinical trials that focused on their impact on clinically relevant endpoints. EXPERT OPINION: STOPP/START criteria are widely used in several countries within Europe and beyond for medication review and audit. As a discreet intervention, the criteria have been tested in several single-center and two large-scale multi-center clinical trials. The single-center trials indicate that STOPP/START criteria reduce polypharmacy, inappropriate prescribing, ADRs (adverse drug reactions), medication cost and falls. In contrast, the SENATOR and OPERAM multicentre trials did not demonstrate significant reduction in ADRs, all-cause mortality, drug-related hospital readmissions, nor any improvement in quality-of-life. Further clinical trials are required to examine whether STOPP/START criteria as an intervention can deliver significant clinical benefit in a reproducible manner in various clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University College Cork, Cork, Ireland.
- Department of Geriatric Medicine, Cork University Hospital, Wilton, Cork, Ireland.
Zitieren
APA
McGettigan, S., Curtin, D., & O'Mahony, D. (2023). STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact. Expert Review of Clinical Pharmacology, 16(12), 1175-1185. https://doi.org/10.1080/17512433.2023.2280219
Vancouver
McGettigan S, Curtin D, O'Mahony D. STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact. Expert Review of Clinical Pharmacology. 2023;16(12):1175-1185. doi:10.1080/17512433.2023.2280219
BibTeX
@article{McGettigan2023,
author = {McGettigan, Siobhán and Curtin, Denis and O'Mahony, Denis},
title = {STOPP/START criteria for potentially inappropriate medications/potential prescribing omissions in older people: uptake and clinical impact},
journal = {Expert Review of Clinical Pharmacology},
year = {2023},
volume = {16},
number = {12},
pages = {1175--1185},
doi = {10.1080/17512433.2023.2280219}
}
EUVIMED